Risk factors for thrombolysis-related intracranial hemorrhage: a systematic review and meta-analysis
Open Access
- 14 March 2023
- journal article
- review article
- Published by Springer Nature in Thrombosis Journal
- Vol. 21 (1) , 1-8
Abstract
Background: Thrombolysis-related intracranial hemorrhage has a high mortality rate, and many factors can cause intracranial hemorrhage. Until now, systematic reviews and assessments of the certainty of the evidence have not been updated.Aim: We conducted a systematic review to identify risk factors for thrombolysis-related intracranial hemorrhage.Method: The protocol for this systematic review was prospectively registered with PROSPERO (CRD42022316160). All English studies that met the inclusion criteria published before January 2022 were obtained from PubMed, EMBASE, Web of Science, and Cochrane Library. Two researchers independently screened articles, extracted data, and evaluated the quality and evidence of the included studies. Risk factors for intracranial hemorrhage were used as the outcome index of this review. Random or fixed-effect models were used in statistical methods.Results: Of 6083 citations, we included 105 studies in our analysis. For intracranial hemorrhage, moderate-certainty evidence showed a probable association with age, National Institutes of Health stroke scale, leukoaraiosis, hypertension, atrial fibrillation, diabetes, total cholesterol, proteinuria, fibrinogen levels, creatinine, homocysteine, early infarct signs, antiplatelet therapy and anticoagulant therapy; In addition, we found low-certainty evidence that there may be little to no association between risk of intracranial hemorrhage and weight, sex, platelet count, uric acid, albumin and white matter hyperintensity. Leukoaraiosis, cardiovascular disease, total cholesterol, white blood cell count, proteinuria, fibrinogen levels, creatinine, homocysteine and early CT hypodensities are not included in most intracranial hemorrhage risk assessment models.Conclusion: This study informs risk prediction for thrombolysis-related intracranial hemorrhage, it also informs guidelines for intracranial hemorrhage prevention and future research.Keywords
This publication has 16 references indexed in Scilit:
- Assessing Bias in Studies of Prognostic FactorsAnnals of Internal Medicine, 2013
- Converting Odds Ratio to Relative Risk in Cohort Studies with Partial Data InformationJournal of Statistical Software, 2013
- Antithrombotic and Thrombolytic Therapy for Ischemic StrokeChest, 2012
- Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trialsThe Lancet, 2010
- Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an updateJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Including Non‐Randomized Studies2008
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic StrokeStroke, 1997
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995